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Proteasome inhibitors are novel therapeutic agents which might be used for the 
treatment of hepatocarcinoma and other liver diseases as they are able to induce 
cell death in proliferating cells specifically. The analysis of alternative protein 
phosphorylation states might contribute to elucidate the underlying mechanisms of 
proteasome inhibitor-induced apoptosis. In the present study we have investigated 
the response of MLP-29 liver cells to MG132 using a combination of phosphoprotein 
affinity chromatography, Differential in Gel Electrophoresis (DIGE), and nanoLC-MS/
MS. Seventeen spots corresponding to 13 unique deregulated phosphoproteins were 
unambiguously identified, which are involved in chaperone activity, stress response, 
mRNA processing and cell cycle control. Some of these protein species, including 
NDRG1 protein, hnRNP A2/B1, and stathmin suggest new mechanisms associated 
to proteasome inhibitor-induced apoptosis in proliferating liver cells. Particularly, a 
transient modification of the phosphorylation state of Ser16, Ser25 and Ser38, which are 
involved in the regulation of stathmin activity, was detected in three distinct isoforms 
upon proteasome inhibition. The parallel deregulation of calcium/calmodulin-activated 
protein kinase II (CaMKII), extracellular regulated kinase (ERK1/2) and cyclin-
dependent kinase (CDK2), catalyzing the phosphoryl group addition to these Ser residues, 
might explain the modified phosphorylation pattern of stathmin. Interestingly, stathmin 
phosphorylation profile was also modified in response to epoxomicin treatment, a more 
specific proteasome inhibitor. In summary, besides impairment of proteins participating 
in central cellular pathways, we report here novel mechanisms involved in proteasome 
inhibition-induced apoptosis that regulate the stathmin phosphorylation status in liver 
proliferating cells.
